Leerink Partnrs Has Negative Outlook of Revvity Q1 Earnings

Revvity, Inc. (NYSE:RVTY) – Leerink Partnrs lowered their Q1 2025 earnings estimates for Revvity in a report issued on Friday, November 22nd. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings of $1.09 per share for the quarter, down from their previous estimate of $1.14. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Leerink Partnrs also issued estimates for Revvity’s Q4 2025 earnings at $1.47 EPS.

A number of other research analysts also recently commented on the company. Wells Fargo & Company began coverage on Revvity in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $130.00 target price for the company. Robert W. Baird increased their price objective on shares of Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Raymond James boosted their target price on shares of Revvity from $144.00 to $146.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Citigroup increased their price target on shares of Revvity from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. Finally, Sanford C. Bernstein reduced their price objective on Revvity from $150.00 to $145.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.73.

Revvity Price Performance

Shares of Revvity stock opened at $115.14 on Monday. The firm has a market cap of $14.01 billion, a PE ratio of 55.62, a PEG ratio of 2.80 and a beta of 1.05. The stock has a 50 day moving average of $120.22 and a 200 day moving average of $115.89. The company has a current ratio of 3.56, a quick ratio of 2.97 and a debt-to-equity ratio of 0.40. Revvity has a 12 month low of $86.30 and a 12 month high of $129.50.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.28 EPS for the quarter, topping the consensus estimate of $1.13 by $0.15. The business had revenue of $684.10 million for the quarter, compared to analysts’ expectations of $679.66 million. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.18 EPS.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.24%. The ex-dividend date of this dividend is Friday, January 17th. Revvity’s dividend payout ratio (DPR) is presently 13.53%.

Revvity declared that its Board of Directors has approved a share buyback program on Monday, November 4th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to purchase up to 6.5% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In related news, insider Tajinder S. Vohra sold 2,154 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $121.73, for a total value of $262,206.42. Following the transaction, the insider now owns 19,652 shares of the company’s stock, valued at $2,392,237.96. This represents a 9.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Revvity

Institutional investors and hedge funds have recently bought and sold shares of the company. EntryPoint Capital LLC bought a new position in shares of Revvity during the first quarter valued at approximately $48,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Revvity by 1.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 168,547 shares of the company’s stock valued at $17,698,000 after acquiring an additional 2,153 shares during the period. California State Teachers Retirement System raised its position in shares of Revvity by 0.8% in the 1st quarter. California State Teachers Retirement System now owns 196,168 shares of the company’s stock worth $20,598,000 after acquiring an additional 1,484 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Revvity by 516.4% during the 1st quarter. Jane Street Group LLC now owns 453,343 shares of the company’s stock worth $47,601,000 after purchasing an additional 379,802 shares during the last quarter. Finally, Wahed Invest LLC boosted its position in Revvity by 13.6% during the first quarter. Wahed Invest LLC now owns 2,399 shares of the company’s stock valued at $252,000 after purchasing an additional 288 shares in the last quarter. 86.65% of the stock is owned by institutional investors.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.